ESP-31015

Details

Stereochemistry	ACHIRAL
Molecular Formula	C17H34O3
Molecular Weight	286.4501
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)(CO)CCCCC(=O)CCCCC(C)(C)CO

InChI

InChIKey=FGTDNJHSEFINNG-UHFFFAOYSA-N

InChI=1S/C17H34O3/c1-16(2,13-18)11-7-5-9-15(20)10-6-8-12-17(3,4)14-19/h18-19H,5-14H2,1-4H3

HIDE SMILES / InChI

Molecular Formula	C17H34O3
Molecular Weight	286.4501
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 11:29:07 GMT 2023` Edited by `admin` on `Sat Dec 16 11:29:07 GMT 2023`
Record UNII	G6QP69A673
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ESP-31015

Code

English

ETC-1001

Code

English

ETC1001

Code

English

7-TRIDECANONE, 1,13-DIHYDROXY-2,2,12,12-TETRAMETHYL-

Systematic Name

English

ESP31015

Code

English

1,13-DIHYDROXY-2,2,12,12-TETRAMETHYL-TRIDECAN-7-ONE

Systematic Name

English

Code System Code Type Description

CAS

413624-55-2

Created by admin on Sat Dec 16 11:29:07 GMT 2023 , Edited by admin on Sat Dec 16 11:29:07 GMT 2023

PRIMARY

PUBCHEM

9925917

Created by admin on Sat Dec 16 11:29:07 GMT 2023 , Edited by admin on Sat Dec 16 11:29:07 GMT 2023

PRIMARY

DRUG BANK

DB05866

Created by admin on Sat Dec 16 11:29:07 GMT 2023 , Edited by admin on Sat Dec 16 11:29:07 GMT 2023

PRIMARY

FDA UNII

G6QP69A673

Created by admin on Sat Dec 16 11:29:07 GMT 2023 , Edited by admin on Sat Dec 16 11:29:07 GMT 2023

PRIMARY

Related Record Type Details


					G6QP69A673

ESP-31015

ACTIVE MOIETY

Comments:

Description: ETC-1001 is Pfizers lead oral small molecule product candidate which is intended to be a chronic treatment for individuals with lipid disorders. Indication: Investigated for use/treatment in hyperlipidemia. Mechanism of action: ETC-1001 is a synthetic, orally-active lipid regulating agent designed to elevate levels of high-density lipoprotein cholesterol (HDL-C), the "good" cholesterol. In pre-clinical studies, it shows the ability to elevate HDL-cholesterol levels, while also reducing levels of low-density lipoprotein cholesterol (LDL-C), the "bad" cholesterol, and triglycerides. It also inhibits the progression of atherosclerosis in pre- clinical models.


					G6QP69A673

ESP-31015

ACTIVE MOIETY

Comments:

Class: Small molecule; Mechanism of Action: Undefined mechanism Highest; Development Phases: Discontinued For Atherosclerosis, Diabetes mellitus and Low HDL cholesterol; Most Recent Events: 29 Apr 2002 Discontinued - Preclinical for Low HDL cholesterol in USA (unspecified route), 29 Apr 2002 Discontinued - Preclinical for Diabetes mellitus in USA (unspecified route), 29 Apr 2002 Discontinued - Preclinical for Atherosclerosis in USA (unspecified route)